PP
RYTM icon

PDT Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

PDT Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,232
Closed -$2.37M – 597
2026
Q1 		$2.37M Sell
27,232
-32,204
-54% -$3.13M 0.14% 220
2025
Q4 		$6.36M Sell
59,436
-26,700
-31% -$2.83M 0.41% 61
2025
Q3 		$8.7M Sell
86,136
-11,502
-12% -$1.07M 0.55% 34
2025
Q2 		$6.17M Sell
97,638
-4,557
-4% -$279K 0.35% 67
2025
Q1 		$5.41M Buy
102,195
+58,612
+134% +$3.25M 0.38% 57
2024
Q4 		$2.44M Buy
43,583
+32,083
+279% +$1.77M 0.22% 160
2024
Q3 		$602K Sell
11,500
-10
-0.1% -$479 0.05% 466
2024
Q2 		$473K Buy
+11,510
New +$459K 0.04% 475
2018
Q4 		– Sell
-17,207
Closed -$502K – 505
2018
Q3 		$502K Sell
17,207
-22,193
-56% -$701K 0.02% 361
2018
Q2 		$1.23M Buy
39,400
+1,693
+4% +$46.3K 0.05% 306
2018
Q1 		$750K Buy
+37,707
New +$1M 0.03% 394

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PDT Partners's RYTM Position: Q2 2026 in Review

PDT Partners sold out of Rhythm Pharmaceuticals (RYTM) in Q2 2026, closing a stake of 27,232 shares — an estimated $2.37M sold.

PDT Partners first reported a position in RYTM in Q1 2018 and held it in 11 quarters. The position peaked at $8.7M in Q3 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • PDT Partners reported no remaining Rhythm Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • PDT Partners sold 27,232 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.37M.
  • PDT Partners first reported a position in Rhythm Pharmaceuticals in Q1 2018 and held it in 11 quarters.
  • PDT Partners's Rhythm Pharmaceuticals position peaked at $8.7M in Q3 2025.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.